Short Interest in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Declines By 31.9%

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 5,220,000 shares, a drop of 31.9% from the October 31st total of 7,670,000 shares. Based on an average daily volume of 37,050,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 2.8% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a research report on Friday. They issued a “sell” rating on the stock.

Tonix Pharmaceuticals Stock Performance

Shares of Tonix Pharmaceuticals stock traded up $0.00 during midday trading on Friday, hitting $0.19. The company had a trading volume of 24,708,578 shares, compared to its average volume of 14,031,304. The business’s 50 day simple moving average is $0.15 and its two-hundred day simple moving average is $1.09. The stock has a market cap of $35.58 million, a PE ratio of 0.00 and a beta of 2.06. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. Tonix Pharmaceuticals has a 1-year low of $0.12 and a 1-year high of $22.14.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $1.80. The business had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. As a group, equities analysts predict that Tonix Pharmaceuticals will post -18 EPS for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.